Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ: OCUL )

8.090 +0.080 (+1.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Expert Ratings for Ocular Therapeutix
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
What 5 Analyst Ratings Have To Say About Ocular Therapeutix
Via Benzinga
Looking Into Ocular Therapeutix's Return On Capital Employed
Via Benzinga
The Latest Analyst Ratings for Ocular Therapeutix
Via Benzinga
Earnings Outlook For Ocular Therapeutix
Via Benzinga
Why Shares of Ocular Therapeutix Jumped This Week
A promising report of a therapy in a phase 1 trial gave the stock a lift. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023
Via Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,... 
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Tesla, Solaredge, Palantir, Cleveland-Cliffs, Ocular Therapeutix: Why These 5 Stocks Are Drawing Heavy Attention Today
Major Wall Street indices closed over 1% higher on Monday ahead of the release of the consumer price index report on Tuesday. The Nasdaq Composite closed 1.48% higher while the S&P 500 ended the... 
Via Benzinga
Dow Gains Over 300 Points; S&P 500 Up 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 300 points on Monday. The Dow traded up 1.01% to 34,211.29 while the NASDAQ rose 1.52% to 11,896.33. The S&P 500... 
Via Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday. The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500... 
Via Benzinga
Teradata, Monday.Com And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Open Higher; Dow Jumps 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday. Following the market opening Monday, the Dow traded up 0.59% to 34,069.23 while the NASDAQ rose 0.65% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday! 
Via InvestorPlace
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday saw 196 companies set new 52-week lows. 
Via Benzinga
AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials
Visit https://www.startengine.com/aiviva to invest in AiViva’s StartEngine Campaign. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
Ocular Therapeutix And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones dipped by more than 600 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.